What Psilocybin Actually Is
Psilocybin is a prodrug — a compound that is pharmacologically inactive until the body converts it into its active form. The molecule itself, 4-phosphoryloxy-N,N-dimethyltryptamine, cannot cross the blood-brain barrier in meaningful quantities. What produces the psychedelic experience is psilocin: 4-hydroxy-N,N-dimethyltryptamine, the product of rapid enzymatic dephosphorylation that occurs as soon as psilocybin enters the bloodstream.
This distinction matters for several practical reasons. The rate at which psilocybin converts to psilocin influences onset timing. Individual variation in the relevant enzymes (primarily alkaline phosphatase) contributes to the variability in onset time — ranging from 20 minutes to over 90 minutes depending on the person, their stomach contents, and their metabolic profile.
From Ingestion to Absorption
When psilocybin-containing mushrooms are consumed orally, the following sequence occurs:
Gastric phase: The mushroom biomass is broken down by stomach acid. The psilocybin is released from the chitin matrix of the mushroom cell walls. Fatty and high-fiber meals slow gastric emptying and can delay onset by 30-60 minutes. Lemon tek — soaking dried mushrooms in citric acid before ingestion — accelerates conversion to psilocin in the stomach, producing faster onset and often a more acute but shorter experience.
Intestinal absorption: Psilocybin is absorbed across the intestinal wall into portal circulation. Alkaline phosphatase activity begins converting psilocybin to psilocin during this transit. By the time the compound reaches the liver, much of it is already in psilocin form.
First-pass metabolism: The liver further processes psilocin, partly conjugating it with glucuronic acid for eventual renal excretion. Some psilocin escapes first-pass metabolism and enters systemic circulation, where it crosses the blood-brain barrier.
Oral bioavailability of psilocybin is estimated at approximately 52 percent, meaning roughly half of the ingested dose reaches systemic circulation as active psilocin.
The Primary Mechanism: 5-HT2A Agonism
Psilocin is a structural analog of serotonin. It binds with high affinity to serotonin receptors — particularly the 5-HT2A subtype — throughout the cortex and limbic system. 5-HT2A receptors are highly concentrated in the prefrontal cortex, a region involved in abstract thinking, self-referential processing, and executive function.
Activation of 5-HT2A receptors in the prefrontal cortex triggers several downstream effects:
- Glutamate release: 5-HT2A agonism stimulates excitatory glutamate activity, which drives the hyperstimulated, hyperconnected patterns of brain activity visible on fMRI during psilocybin sessions.
- Default mode network suppression: The default mode network (DMN) — a set of brain regions active during self-referential thinking, rumination, and mind-wandering — shows reduced activity and disrupted internal coherence under psilocybin. This is the neurological correlate of ego dissolution and altered self-perception.
- Thalamocortical filter loosening: The thalamus normally acts as a gatekeeper, filtering sensory and associative information before it reaches consciousness. Psilocybin appears to reduce this filtering, which is associated with the sensory enhancement and synesthesia commonly reported during sessions.
Psilocin also binds to 5-HT1A, 5-HT2C, and other serotonin receptor subtypes, as well as dopamine receptors, though the clinical significance of these secondary bindings is less well established.
Timeline of Effects
| Phase | Approximate timing | What happens | |---|---|---| | Onset | 20-90 min post-ingestion | First effects: yawning, visual brightening, emotional shift | | Ascent | 60-120 min | Increasing intensity, possible nausea, perceptual changes | | Peak | 2-4 hours post-ingestion | Full psychedelic state, possible ego dissolution | | Plateau | 1-2 hours | Sustained peak or slow descent | | Descent | 4-6 hours | Gradual return to baseline, often reflective | | Afterglow | 6-24 hours | Residual mood elevation, fatigue, openness |
Typical session duration for a moderate to high dose is 4-6 hours. The total window from ingestion to full sobriety is typically 6-8 hours for most adults.
Half-Life and Elimination
Psilocin has a plasma half-life of approximately 2-3 hours. This is shorter than many psychoactive compounds, which helps explain the relatively predictable 4-6 hour session window. Urine drug screens detect psilocin metabolites for 1-3 days in most individuals, though this can extend up to one week with heavy use.
The compound is primarily excreted through the kidneys. Individuals with reduced renal function may experience longer durations and higher peak plasma levels than healthy adults at equivalent doses. No cytochrome P450 enzyme has been definitively identified as the primary metabolizer of psilocin, which means drug interactions via CYP pathways are less predictable than for many other substances.
Pharmacological Basis for Tolerance
Tolerance to psilocybin develops rapidly through receptor downregulation — primarily 5-HT2A desensitization. After a single psilocybin dose, sensitivity is significantly reduced for approximately two weeks. Cross-tolerance exists with LSD and mescaline (also 5-HT2A agonists) but not with most other psychoactive compounds, and not with MDMA.
This is why responsible use guidelines recommend intervals of two to four weeks between sessions, and why clinical trials space sessions 2-4 weeks apart. The rapid tolerance development also means psilocybin has essentially no addiction potential by the pharmacological mechanism by which opioids, stimulants, and alcohol create physical dependence.
Serotonin Syndrome Risk
Because psilocybin acts on serotonin receptors, combining it with other serotonergic medications carries theoretical risk of serotonin syndrome — a potentially dangerous state of serotonin excess. This interaction is most relevant for:
- SSRIs and SNRIs (which also elevate serotonin activity)
- MAOIs (which prevent serotonin breakdown and can dramatically intensify and prolong psilocybin effects)
- Lithium (which sensitizes serotonergic systems and has been associated with seizure risk when combined with psilocybin in case reports)
SSRIs and SNRIs also blunt the subjective effects of psilocybin through receptor downregulation, meaning people on these medications may experience reduced psychedelic effects at standard doses — a clinical variable relevant to both therapeutic contexts and personal use.